1. Hong Kong Stocks

  2. •

    Basic Materials

  3. •

    Construction Materials
Kontafarma China Holdings Ltd

Kontafarma China Holdings Ltd

1312.HK
Kontafarma China Holdings LtdHK flagHong Kong Stock Exchange
0.03
HKD
+0.00
- -
156.20MMarket Cap
Kontafarma China Holdings Ltd
1312.HK
(Hong Kong Stock Exchange)

Recent

price

0.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.26
0.41
0.22
0.18
0.18
0.09
0.13
0.27
0.38
0.17
0.18
0.14
0.16
0.15
0.16
- -
Revenue per Share
0.1
0.04
0.01
0.01
- -
-0.01
-0.01
- -
0.01
0.01
-0.05
- -
-0.01
-0.01
-0.01
- -
Basic EPS, GAAP
0.01
-0.02
-0.01
-0.02
-0.01
-0.02
-0.01
-0.03
- -
-0.01
- -
-0.01
-0.01
- -
0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.15
0.19
0.11
0.1
0.1
0.07
0.06
0.06
0.06
0.07
0.02
0.02
0.01
0.01
-0.01
- -
Book Value per Share
0.36
0.55
0.36
0.3
0.43
0.32
0.28
0.2
0.19
0.19
0.09
0.1
0.08
0.09
0.07
- -
Tangible Book Value per Share
1,764
1,787
3,262
3,976
4,000
4,950
4,950
4,944
5,455
5,579
5,579
5,579
5,579
5,579
5,579
- -
Basic Weighted Avg Shares
451
725
705
703
733
466
633
1,344
2,094
921
1,009
803
894
809
898
915
Sales/Revenue/Turnover
130.59
13.85
4.62
4.62
5.02
-2.89
-6.04
5.66
8.64
4.4
3.46
-7.25
-10.87
-16.76
-5.28
-25.41
Operating Margin (%)
12
19
21
22
22
23
29
57
81
160
146
145
131
107
99
91
Depreciation Expense
168
76
27
33
17
-34
-37
-2
32
36
-267
-15
-42
-29
-76
-428
Net Income, GAAP
27.35
24.89
20.17
26.18
39.22
- -
- -
0.33
34.31
18.72
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
37.29
10.5
3.81
4.63
2.36
-7.35
-5.85
-0.13
1.55
3.92
-26.47
-1.87
-4.65
-3.56
-8.42
-46.77
Profit Margin (%)
399
665
686
790
1,396
1,150
844
511
381
419
150
78
185
204
115
-91
Working Capital
86
30
42
66
185
- -
163
177
1
368
467
422
368
228
147
75
LT Debt
647
994
1,161
1,210
1,714
1,609
1,643
1,849
1,909
1,921
1,354
1,338
1,156
1,062
962
476
Total Equity
- -
6.99
1.96
1.74
1.24
- -
- -
2.72
4.44
1.19
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
8.16
2.25
2.54
1.44
- -
- -
-0.97
1.41
1.48
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
25.07
7.62
8.82
4.54
-9.39
-11.26
-0.58
9.94
9.99
-106.78
-13.35
-48.91
-57.98
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.38%
-16.57%
-50.47%
Free Cash Flow
2.45%
-37.33%
59.1%
Net Income, GAAP
-213.58%
135.89%
466.41%
Sales/Revenue/Turnover
15.18%
-1.15%
1.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
809
2024
- -
- -
- -
- -
898
2025
- -
- -
- -
- -
915

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
The Monarch Cement Company (MCEM)
ROY Asset Holding SE (RY8.F)
Sergeferrari Group (ALFER.PA)
Recticel SA/NV (RECT.BR)
China Kingstone Mining Holdings Ltd (1380.HK)
ReTo Eco-Solutions, Inc. (RETO)
Business
Kontafarma China Holdings Limited (1312.HK) is an investment holding company principally engaged in the manufacture and sale of prescription drugs and the operation of fitness centers. Incorporated in the Cayman Islands in 2011 and listed on the Hong Kong Stock Exchange in 2012, the company is headquartered in Wan Chai, Hong Kong, and operates primarily through its subsidiaries in Mainland China, with additional reach in Singapore, Taiwan, and internationally; it is a subsidiary of China Health Management Investment Limited. The Pharmaceutical Business segment manufactures and sells chemical drugs, active pharmaceutical ingredients (API), API intermediates, prescribed traditional Chinese medicines, injection powders, tablets, capsules, ointments, synthetic drugs, preparations, biochemical drugs, and laboratory-related products, adhering to GMP standards in its plants and including chloroquine phosphate for pneumonia treatment; the Fitness Business segment operates fitness and yoga centers, provides consultation services for fitness and health activities, and manages franchise operations for royalty income. In a key development, a subsidiary entered into a contract in 2025 valued at RMB33.7 million for constructing a Beijing R&D complex to bolster research and development capabilities, with the transaction approved at an adjourned extraordinary general meeting; the company also reported interim results for the six months ended June 30, 2025, reflecting revenue of HKD453 million and a net loss amid fitness segment challenges; it previously acquired Tongfang Pharmaceutical Group Co., Ltd. (formerly Beijing Ziguang Pharmaceutical Co., Ltd.) in 2016 and changed its name from Tongfang Kontafarma Holdings Limited in September 2022.